CordenPharma to Acquire Peptisyntha SA from Solvay - - BioPharm International

ADVERTISEMENT

CordenPharma to Acquire Peptisyntha SA from Solvay



International Chemical Investors Group (ICIG) and the Solvay Group have formed an agreement under which ICIG will acquire Peptisyntha SA, the Brussels-based custom manufacturer of peptides. Upon closing of the deal, expected later this fall, Peptisyntha will become a member of ICIG’s CordenPharma platform as its third site offering peptide manufacturing.

Although the US sister company Peptisyntha Inc., located in Torrance, California, is not part of the transaction, certain customer relationships will be assumed by Peptisyntha in Brussels.

Source: CordenPharma

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines

Click here